Elevated serum level of B‐cell activating factor ( <scp>BAFF</scp> ) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with <scp>anti‐BAFF</scp> agents-Reference-Cited by-同舟云学术

Elevated serum level of B‐cell activating factor ( BAFF ) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with anti‐BAFF agents

Published:2022-07-27 Issue:4 Volume:62 Page:567-574
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Daneshvar Elham¹,Tavakolpour Soheil¹²^ORCID,Mahmoudi Hamidreza¹³,Daneshpazhooh Maryam¹³^ORCID,Teimourpour Amir¹,Aslani Saeed⁴,Balighi Kamran¹³

Affiliation:

1. Department of Dermatology Razi Hospital, Tehran University of Medical Sciences Tehran Iran

2. Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA

3. Autoimmune Bullous Diseases Research Center Razi Hospital, Tehran University of Medical Sciences Tehran Iran

4. Department of Immunology School of Medicine, Tehran University of Medical Sciences Tehran Iran

Funder

Tehran University of Medical Sciences and Health Services

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.16363

Reference36 articles.

1. Pemphigus

2. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches

3. ELISA Testing of Anti–Desmoglein 1 and 3 Antibodies in the Management of Pemphigus

4. Pemphigus patients with initial negative levels of anti‐desmoglein: A subtype with different profile?

5. Recognition of Desmoglein 3 by Autoreactive T Cells in Pemphigus Vulgaris Patients and Normals

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates on the Management of Autoimmune Bullous Diseases;Indian Dermatology Online Journal;2024-08-30

2. What is novel in the clinical management of pemphigus vulgaris?;Expert Review of Clinical Pharmacology;2024-05-12

3. Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992–2022);Heliyon;2024-04

4. Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?;Journal of Cosmetic Dermatology;2023-11-02

5. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin;American Journal of Clinical Dermatology;2023-01-11